8-K: Perrigo Reports Mixed Q2 Results, Reaffirms Full-Year EPS Outlook Despite Sales Dip

Perrigo's second quarter results show a decline in net sales, primarily due to infant formula issues and lower seasonal demand, but the company maintains its full-year adjusted EPS outlook.

Summary

• Perrigo's net sales for the second quarter of 2024 decreased by 10.7% to $1.1 billion compared to the same period last year.
• Organic net sales declined by 9.1%, with significant impacts from lower infant formula sales (-6.8 percentage points) and reduced demand in upper respiratory and pain & sleep aids categories (-4.0 percentage points).
• Consumer Self-Care International (CSCI) net sales decreased by 2.5%, while Consumer Self-Care Americas (CSCA) net sales fell by 15.5%.
• The company's GAAP operating loss was $(27) million, a significant drop from the $57 million income in the prior year quarter.
• Adjusted operating income increased slightly by 1.5% to $139 million, but excluding the impact of infant formula, it grew by 16.7%.
• Reported diluted loss per share was $(0.77), compared to earnings of $0.06 in the prior year quarter, while adjusted diluted EPS was $0.53, down from $0.63.
• Perrigo has updated its fiscal 2024 organic net sales growth outlook to -3% to -1% from +1% to +3%, and total net sales growth outlook to -5% to -3% from flat.
• The company reaffirmed its fiscal 2024 adjusted diluted EPS outlook of $2.50-$2.65.
• Project Energize, a three-year efficiency program, is expected to deliver $140 million to $170 million in annualized pre-tax savings by 2026, with $40 million to $60 million reinvested.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company reaffirms its EPS outlook and highlights cost-saving initiatives, the significant sales decline and operating loss raise concerns. The positive aspects are somewhat offset by the challenges in the infant formula business and the reduced sales outlook.

Positives

• Adjusted gross margin expanded by 190 basis points to 40.6%.
• Adjusted operating income increased by 1.5% to $139 million, and grew 16.7% excluding the impact of infant formula.
• Project Energize is expected to deliver significant cost savings.
• The company reaffirmed its full-year adjusted EPS outlook.
• The divestment of the HRA Pharma Rare Diseases business was completed, bringing in $205 million in upfront proceeds.

Negatives

• Net sales decreased by 10.7% to $1.1 billion in Q2 2024 compared to the prior year quarter.
• Organic net sales declined by 9.1%, primarily due to infant formula issues and lower seasonal demand.
• Reported operating loss was $(27) million, a significant drop from the $57 million income in the prior year quarter.
• Reported diluted loss per share was $(0.77), compared to earnings of $0.06 in the prior year quarter.
• Adjusted diluted EPS was $0.53, a decrease of $0.10 per share due to prior year tax benefits and infant formula impacts.
• The company updated its fiscal 2024 organic net sales growth outlook to -3% to -1% from +1% to +3%, and total net sales growth outlook to -5% to -3% from flat.

Risks

• The company faces challenges in the infant formula regulatory environment in the U.S.
• Lower seasonal demand impacted sales in the Upper Respiratory and Pain & Sleep Aids categories.
• The company expects lower distribution in U.S. store brand in the second half of 2024.
• Restructuring activities as part of Project Energize are expected to result in the net reduction of approximately 6% of total Perrigo roles.
• The company is exposed to fluctuations in currency exchange rates and interest rates.

Future Outlook

Perrigo has updated its fiscal 2024 organic net sales growth outlook to -3% to -1% and total net sales growth outlook to -5% to -3%. The company reaffirmed its fiscal 2024 adjusted diluted EPS outlook of $2.50-$2.65.

Management Comments

• President and CEO, Patrick Lockwood-Taylor, stated that the company is progressing its blueprint to build One Perrigo by driving efficiency programs and simplifying the business.
• Lockwood-Taylor noted challenges in the infant formula regulatory environment but expressed confidence in the second half profit recovery of this business.
• Management believes that adjusted gross margin and adjusted operating margin are useful to investors by allowing them to more easily compare and analyze trends in the company's peer business group.

Industry Context

Perrigo operates in the consumer self-care industry, which is subject to seasonal demand fluctuations and regulatory changes, particularly in the infant formula sector. The company's performance is also influenced by competition and pricing pressures.

Comparison to Industry Standards

• Perrigo's performance is being compared to other consumer healthcare companies, particularly in terms of gross margin and operating margin.
• The company's adjusted gross margin of 40.6% and adjusted operating margin of 13.1% are key metrics for comparison with peers like Haleon, Johnson & Johnson Consumer Health, and Sanofi Consumer Healthcare.
• The impact of infant formula issues on Perrigo's sales is a unique challenge, but the company's efforts to improve its supply chain and product mix are similar to strategies employed by other companies in the sector.
• The Project Energize cost-saving program is a common strategy in the industry to improve profitability and efficiency, similar to restructuring programs at other large consumer goods companies.

Stakeholder Impact

• Shareholders may be concerned about the sales decline and operating loss, but reassured by the reaffirmed EPS outlook.
• Employees may be affected by the restructuring activities under Project Energize.
• Customers may experience changes in product availability due to supply chain adjustments and SKU prioritization.
• Suppliers may be impacted by changes in the company's supply chain strategy.

Next Steps

• The company will continue to execute Project Energize to drive cost savings and improve efficiency.
• Perrigo will focus on improving its infant formula business and supply chain.
• The company will monitor and respond to seasonal demand fluctuations and market trends.

Key Dates

Keywords

Perrigo, Consumer Self-Care, Infant Formula, Project Energize, Net Sales, EPS, Gross Margin, Operating Income, Restructuring, Divestment